Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)

Trial Profile

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omaveloxolone (Primary)
  • Indications Mitochondrial myopathies
  • Focus Therapeutic Use
  • Acronyms MOTOR
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 02 Apr 2018 Status changed from recruiting to completed.
    • 01 Mar 2018 Top-line data from the dose-escalation cohorts (n = 53) presented in a Reata Pharmaceuticals media release.
    • 03 Mar 2017 According to a Reata Pharmaceuticals media release, data from this first part of this trial are expected in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top